Amgen (BSP:AMGN34) Machinery, Furniture, Equipment : R$22,245 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Amgen Machinery, Furniture, Equipment?

Amgen's Machinery, Furniture, Equipment for the quarter that ended in Dec. 2023 was R$22,245 Mil.

Amgen's quarterly Machinery, Furniture, Equipment stayed the same from Jun. 2023 (R$0 Mil) to Sep. 2023 (R$0 Mil) but then increased from Sep. 2023 (R$0 Mil) to Dec. 2023 (R$22,245 Mil).

Amgen's annual Machinery, Furniture, Equipment declined from Dec. 2021 (R$23,926 Mil) to Dec. 2022 (R$22,660 Mil) and declined from Dec. 2022 (R$22,660 Mil) to Dec. 2023 (R$22,245 Mil).

Amgen Machinery, Furniture, Equipment Historical Data

The historical data trend for Amgen's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Machinery, Furniture, Equipment Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Machinery, Furniture, Equipment

Get a 7-Day Free Trial

15,634.04

20,995.52

23,925.88

22,660.13

22,245.09

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Machinery, Furniture, Equipment	Get a 7-Day Free Trial															22,660.13	-	-	-	22,245.09

Amgen Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.

Amgen (BSP:AMGN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BSP:AMGN34) » Definitions » Machinery, Furniture, Equipment

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (BSP:AMGN34) Headlines

No Headlines